Milbank LLP represented the initial purchasers in connection with the offering by Almirall, S.A. of €250 million 3.75% senior notes due 2031.
Almirall used the proceeds from the offering together with cash in hand to redeem in full its €300 million senior notes due 2026 and pay related fees and expenses. Almirall is a global research-focused biopharmaceutical company with a leadership position in Europe, dedicated to medical dermatology offering a portfolio of products indicated for the treatment of psoriasis, atopic dermatitis, actinitic keratosis, acne and onychomycosis.
The Milbank team was led by European Leveraged Finance/Capital Markets partner Rebecca Marques, and associates Irene Mainar Borao and Aryan Agrawal. Advice was also provided on German law matters by Corporate Finance & Securities partner Philipp Kloeckner, and associates Nico Feuerstein and Janik Brem. The team had assistance from Tax partner Eschi Rahimi-Laridjani and associate Blake Rocks.
